Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CNTA

Centessa Pharmaceuticals plc ADR

Apr 26 • 04:00PM ET

8.92

Dollar change -0.01
Percentage change -0.11	%

Healthcare • Biotechnology • United Kingdom • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.58	Insider Own	39.49%	Shs Outstand	98.77M	Perf Week	-15.61%
Market Cap	881.03M	Forward P/E	-	EPS next Y	-1.75	Insider Trans	-0.14%	Shs Float	59.77M	Perf Month	-19.64%
Income	-151.72M	PEG	-	EPS next Q	-0.43	Inst Own	36.11%	Short Float	2.15%	Perf Quarter	9.99%
Sales	6.91M	P/S	127.50	EPS this Y	-11.29%	Inst Trans	0.06%	Short Ratio	3.13	Perf Half Y	42.95%
Book/sh	2.39	P/B	3.73	EPS next Y	-0.39%	ROA	-37.59%	Short Interest	1.28M	Perf Year	88.58%
Cash/sh	2.60	P/C	3.43	EPS next 5Y	-	ROE	-53.01%	52W Range	3.96 - 12.45	Perf YTD	12.06%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-47.29%	52W High	-28.35%	Beta	1.46
Dividend TTM	-	Quick Ratio	8.00	Sales past 5Y	0.00%	Gross Margin	88.25%	52W Low	125.25%	ATR (14)	0.74
Dividend Ex-Date	-	Current Ratio	8.00	EPS Y/Y TTM	31.55%	Oper. Margin	-2487.49%	RSI (14)	33.67	Volatility	8.17% 7.12%
Employees	76	Debt/Eq	0.36	Sales Y/Y TTM	-	Profit Margin	-2194.85%	Recom	1.40	Target Price	13.60
Option/Short	Yes / Yes	LT Debt/Eq	0.36	EPS Q/Q	17.46%	Payout	-	Rel Volume	0.62	Prev Close	8.93
Sales Surprise	-	EPS Surprise	22.15%	Sales Q/Q	-	Earnings	Mar 28 AMC	Avg Volume	409.97K	Price	8.92
SMA20	-16.45%	SMA50	-17.82%	SMA200	11.83%	Trades		Volume	254,924	Change	-0.11%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-15-23	Upgrade	Jefferies	Hold → Buy	$4 → $11
Oct-26-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$4 → $8
Jun-21-23	Initiated	Evercore ISI	Outperform
Jun-12-23	Initiated	Guggenheim	Buy	$9
Mar-17-23	Initiated	SVB Securities	Outperform	$6
Aug-12-22	Downgrade	Morgan Stanley	Overweight → Underweight	$10 → $5
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$19
Jun-03-22	Downgrade	Jefferies	Buy → Hold	$37 → $4
Feb-11-22	Initiated	Goldman	Neutral	$12

Apr-24-24 04:47AM	Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS (MT Newswires)
Apr-23-24 09:36PM	Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares (GlobeNewswire) -6.00%
06:00PM	Centessa Pharmaceuticals Eyes $100 Million in ADS Offering (MT Newswires)
04:17PM	Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares (GlobeNewswire)
Apr-22-24 07:00AM	Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 (GlobeNewswire) -5.39%
11:53PM	Loading…
Mar-28-24 11:53PM	CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
06:11PM	Centessa Pharmaceuticals PLC (CNTA) Earnings: A Detailed Look at Q4 and Full-Year 2023 Results (GuruFocus.com)
04:28PM	Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023 (GlobeNewswire)
Mar-27-24 01:26AM	Centessa Pharmaceuticals PLC Chief People Officer Sells Company Shares (GuruFocus.com)
Mar-18-24 08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace)
Feb-22-24 08:00AM	Centessa Pharmaceuticals to Participate in TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 07:00AM	Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (GlobeNewswire) +24.13%
Jan-22-24 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Dec-13-23 08:00AM	Centessa Pharmaceuticals to Present at the 42 Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-23 12:05PM	Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia (GlobeNewswire)
09:55AM	Loading…
Dec-05-23 09:55AM	Does Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) Have the Potential to Rally 40.85% as Wall Street Analysts Expect? (Zacks)
Nov-27-23 04:15PM	Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals (GlobeNewswire)
Nov-16-23 09:55AM	Wall Street Analysts Predict a 35.92% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know (Zacks)
Nov-14-23 07:28PM	Centessa Pharmaceuticals PLC Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com) +6.25%
Nov-13-23 04:05PM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023 (GlobeNewswire)
Nov-02-23 09:09AM	Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-23 08:00AM	Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors (GlobeNewswire)
Oct-30-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.32%
Oct-25-23 08:00AM	Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750's Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders (GlobeNewswire) -6.02%
Oct-03-23 08:00AM	Centessa Pharmaceuticals Announces Additions to Senior Leadership Team (GlobeNewswire)
Sep-04-23 10:51AM	Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why (Zacks)
Aug-31-23 08:00AM	Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire) +6.35%
Aug-23-23 05:08PM	Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress (GlobeNewswire)
Aug-14-23 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023 (GlobeNewswire)
Jul-10-23 08:00AM	Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors (GlobeNewswire) +5.04%
08:00AM	Loading…
May-24-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-22-23 07:00AM	Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B (GlobeNewswire)
May-12-23 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 (GlobeNewswire)
Apr-27-23 12:07PM	Centessa Pharmaceuticals plc (NASDAQ:CNTA) most popular amongst private equity firms who own 42% of the shares, institutions hold 22% (Simply Wall St.) -5.71%
Mar-30-23 07:00AM	Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022 (GlobeNewswire)
Mar-27-23 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-23-23 04:30PM	Clarivate Announces Gordon Samson as President, Intellectual Property and Nominates Dr. Saurabh Saha as New Independent Director (PR Newswire)
08:32AM	Should You Buy Centessa Pharmaceuticals (CNTA) Ahead of Earnings? (Zacks)
Mar-01-23 08:00AM	Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines (GlobeNewswire)
Feb-06-23 08:00AM	Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) (GlobeNewswire)
Feb-02-23 08:00AM	Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-26-23 09:08AM	Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors (GlobeNewswire)
Dec-10-22 03:30PM	Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia (GlobeNewswire)
Nov-30-22 08:00AM	Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson (GlobeNewswire)
Nov-18-22 10:29AM	While institutions own 29% of Centessa Pharmaceuticals plc (NASDAQ:CNTA), private equity firms are its largest shareholders with 42% ownership (Simply Wall St.)
Nov-10-22 07:00AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022 (GlobeNewswire)
Nov-03-22 09:04AM	Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting (GlobeNewswire)
Oct-31-22 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-20-22 08:33AM	Centessa Pharmaceuticals Announces Poster Presentation Featuring Novel Orexin Receptor 2 (OX2R) Agonist Discovery Pipeline at the 26th Conference of the European Sleep Research Society (Sleep Europe 2022) (GlobeNewswire)
Sep-14-22 09:00AM	Centessa Pharmaceuticals Announces Orphan Drug Designation Granted to SerpinPC for the Treatment of Hemophilia B (GlobeNewswire) +8.92%
Sep-12-22 07:00AM	Centessa Pharmaceuticals Announces Non-Human Primate Pharmacokinetic and Safety Data for LB101 (PD-L1xCD47) Demonstrating Potential for Enhanced Therapeutic Index (GlobeNewswire)
Aug-29-22 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-22 08:37AM	Centessa Culls Early-Stage Asset For Inherited Disorder (Benzinga) -5.19%
06:30AM	Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874 (GlobeNewswire)
Jul-29-22 05:00AM	Why are Massachusetts CEOs paid so much money? Here's a primer (American City Business Journals)
Jul-25-22 08:00AM	Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs (GlobeNewswire)
Jul-01-22 08:40AM	Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors (GlobeNewswire) +6.16%
Jun-23-22 09:55AM	Wall Street Analysts Predict a 128% Upside in Centessa Pharmaceuticals PLC Sponsored ADR (CNTA): Here's What You Should Know (Zacks)
Jun-17-22 02:35PM	BMO Capital Sees Almost 300% Upside On Centessa Stock (Benzinga) +19.08%
Jun-11-22 10:06AM	What Kind Of Investors Own Most Of Centessa Pharmaceuticals plc (NASDAQ:CNTA)? (Simply Wall St.)
Jun-06-22 08:00AM	Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-05-22 07:00AM	Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting (GlobeNewswire)
Jun-03-22 08:29AM	Record-Setting Biotech Plunges 25% After Axing Lead Program (TheStreet.com)
Jun-02-22 06:29AM	Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) (GlobeNewswire) -27.78%
May-16-22 07:00AM	Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-30-22 04:01PM	Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-23-22 04:30PM	Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day (GlobeNewswire)
Mar-07-22 07:30AM	Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise (GlobeNewswire)
Feb-24-22 07:30AM	Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease (GlobeNewswire)
Feb-17-22 02:38AM	Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs Samsara BioCapital (Insider Monkey)
Jan-01-22 07:33AM	Do Institutions Own Centessa Pharmaceuticals Limited (NASDAQ:CNTA) Shares? (Simply Wall St.)
Dec-21-21 06:38PM	Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ... (GuruFocus.com) +10.06%
Dec-14-21 07:30AM	Centessa Pharmaceuticals Initiates Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease, Reports Initial Positive Safety Data from ALERT Study, and Announces Notice of Allowance for Key Lixivaptan U.S. Patent Application (GlobeNewswire) -9.39%
Dec-13-21 04:15PM	Centessa Pharmaceuticals Announces Addition to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-06-21 05:00PM	2 Big Stock Bets That Are Insiders Are Buying Now (InvestorPlace) -5.58%
Nov-24-21 06:59AM	Centessa Pharmaceuticals (CNTA) Sees Hammer Chart Pattern: Time to Buy? (Zacks)
Nov-15-21 07:00AM	Centessa Pharmaceuticals Announces Third Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Nov-10-21 04:45PM	Centessa Pharmaceuticals to Present at Upcoming Conferences in 2021 (GlobeNewswire)
Nov-01-21 07:29PM	Why Did Centessa's Shares Plunge 10% Today? (Benzinga) -18.55%
10:35AM	Mid-Morning Market Update: Markets Mixed; PG&E Earnings Miss views (Benzinga)
07:30AM	Centessa Pharmaceuticals Demonstrates Proof-of-Mechanism from First Three PiMZ Subjects Dosed in Part B of Phase 1 Study Evaluating ZF874 (GlobeNewswire)
Oct-18-21 08:00AM	Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger Announce Collaboration to Discover Novel Orexin Receptor Agonists (Business Wire)
Oct-05-21 08:00AM	Centessa Pharmaceuticals Appoints David Grainger, PhD, a Leading Biotech Entrepreneur, as Chief Innovation Officer (GlobeNewswire)
Oct-04-21 08:00AM	Centessa Pharmaceuticals Announces $300 Million Financing Agreement with Oberland Capital (GlobeNewswire)
Sep-29-21 08:47AM	15 Biotech Stocks to Buy Now According to Srini Akkaraju and Michael Dybbs Samsara BioCapital (Insider Monkey)
Sep-09-21 12:01PM	35 Stocks Moving In Thursday's Mid-Day Session (Benzinga) +5.75%
07:30AM	Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis (GlobeNewswire)
Sep-01-21 04:15PM	Centessa Pharmaceuticals to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference (GlobeNewswire)
Aug-16-21 07:00AM	Centessa Pharmaceuticals Announces Second Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Jul-14-21 08:06AM	Goldman Sachs Sees These 3 Stocks Skyrocketing Over 60% (TipRanks)
Jun-07-21 04:15PM	Centessa Pharmaceuticals to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference (GlobeNewswire)
04:00AM	Citi Appointed as Depositary Bank for Centessa Pharmaceuticals plcs ADR Programme (Business Wire)
Jun-04-21 04:15PM	Centessa Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional ADSs (GlobeNewswire)
May-27-21 10:49PM	Centessa Announces Pricing of Initial Public Offering (Business Wire)

Centessa Pharmaceuticals Plc operates as clinical-stage pharmaceutical company, which engages in discovering and developing medicines that delivers transformational to patients. Its portfolio include preclinical to phase three uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. The company was founded on October 26, 2020 and is headquartered in Altrincham, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anderson Karen M.	Chief People Officer	Mar 25 '24	Option Exercise	3.94	45,000	177,252	122,685	Mar 26 04:16 PM
Anderson Karen M.	Chief People Officer	Mar 25 '24	Sale	11.88	51,160	607,960	71,525	Mar 26 04:16 PM
Rotman Harris	SVP Regulatory Affairs	Feb 01 '24	Sale	8.10	4,267	34,574	62,625	Feb 02 05:03 PM
Rotman Harris	SVP Regulatory Affairs	Sep 20 '23	Option Exercise	4.37	37,484	163,688	70,984	Sep 22 04:47 PM
Rotman Harris	SVP Regulatory Affairs	Sep 20 '23	Sale	6.29	37,484	235,688	33,500	Sep 22 04:47 PM
YVER ANTOINE	EVP & Chairman of Development	Jun 01 '23	Sale	4.45	6,500	28,949	783,066	Jun 02 05:01 PM
Bush Tia L	Chief Quality Officer	May 24 '23	Sale	4.48	8,000	35,865	0	May 26 05:01 PM
YVER ANTOINE	EVP & Chairman of Development	May 01 '23	Sale	4.42	6,800	30,083	789,566	May 02 05:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CNTA

Centessa Pharmaceuticals plc ADR

Upgrade your FINVIZ experience